Hemostemix Stock Price, News & Analysis

Hemostemix (OTCQB: HMTXF) presented ACP-01 clinical highlights at University of Florida Grand Rounds on November 12, 2025, covering safety, efficacy signals, Florida access, and operations.

Key facts: ACP-01 is autologous, >498 treated patients with no cell-related complications reported, observed ~5% absolute LVEF increases in cardiomyopathy cohorts, +126 m 6-minute walk improvements, and a ~5% combined amputation/death rate versus ~40% historical 1-year post-amputation mortality in one dataset. ACP-01 is available in Florida under SB 1768 at a listed therapy price of US$37,000; each procedure will use IRB oversight and a 7-day production cycle.

Hemostemix (OTCQB: HMTXF) announced on November 4, 2025 that it closed the first tranche of a non-brokered private placement, raising $461,230 through issuance of 4,193,000 Units at $0.11 per Unit.

Each Unit includes one common share and one warrant exercisable at $0.15 for two years, with an accelerated expiry if the 10-day weighted average trading price exceeds $0.185 after four months. The company paid cash finder's fees of $23,698.40 and issued 215,440 Finder's Options with the same exercise price for 24 months.

Net proceeds will fund general working capital and marketing for VesCell. Certain directors participated; the company relied on exemptions under MI 61-101. Closing is subject to regulatory acceptance and securities are subject to a four-month hold.

Hemostemix (OTCQB: HMTXF) is expanding patient access to its autologous angiogenic-cell therapy ACP-01 in Florida under Senate Bill 1768, which allows licensed physicians to deliver unapproved stem-cell–based treatments for pain and wound care with safety and consent safeguards. The company has deployed a Florida field team, run webinars since August, and will present Grand Rounds at the University of Florida on November 12, 2025.

Key activities include physician training, streamlined compassionate-use access for Rutherford 4–5 CLTI patients, IRB review for a Basket trial, and patient education materials.

Hemostemix (OTCQB: HMTXF) will host a one-hour educational webinar for Florida vascular surgeons on October 29, 2025 at 12:00 PM ET to review ACP-01 (VesCell), an autologous blood-derived stem cell therapy for no-option chronic limb-threatening ischemia (CLTI).

The session covers ACP-01 science, patient qualification (Rutherford class 4-5 with non-healing ulcers), outpatient administration protocol, Florida compassionate-use pathways (Statute s. 381.985), certification steps, clinical outcomes, and a live Q&A. Attendees receive downloadable screening tools and compliance checklists. Registration: https://streamyard.com/watch/wUA8bPj2cN8w; inquiries: clawrence@hemostemix.com.

Hemostemix (OTCQB: HMTXF) announced that Japan granted registration of the trademark "KNOW YOUR HEALTH" under International Registration No. 1744775 on October 22, 2025, covering Classes 1, 5, and 42.

The registration, issued via the Japanese Patent Office through the WIPO Madrid System, secures brand rights for stem-cell preparations, pharmaceutical/biological compositions including autologous ACP-01 uses, and scientific/clinical services in regenerative medicine. The company says this strengthens its IP position in Japan, aligns the mark with ongoing ACP-01 clinical/special-access programs for ischemic and cardiopulmonary indications, and supports licensing and collaboration opportunities in Japan's research market.

Hemostemix (OTCQB: HMTXF) completed a Phase 1 basket-trial protocol titled Treatment of Refractory Angina with Angiogenic Cell Precursors (ACP-01) dated October 15, 2025. The multi-center, open-label, non-randomized study will enroll 20–100 adults aged 40–90 with refractory severe angina to assess feasibility and safety after intracoronary ACP-01 delivery in an outpatient catheterization setting.

Secondary endpoints include chest-pain frequency, six-minute-walk distance, QoL and Karnofsky scores, emergency-care use, LVEF, and functional class; exploratory endpoints compare one versus two treatments (Day 0 and Day 90) and analyze BNP as a predictor.

Hemostemix (OTCQB: HMTXF) filed an Institutional Review Board application on October 9, 2025 for a Phase 1 study titled "Treatment of Vascular Cognitive Impairment and Dementia with Angiogenic Cell Precursors (ACP-01)."

The open‑label, multi‑center protocol plans 20–100 adults (ages 50–100), intrathecal autologous ACP-01 delivery with an optional second dose at 3 months, and follow‑up at 3, 6, and 12 months. Primary endpoints are safety and feasibility; secondary endpoints include cognition tests, EEG BNA, and MRI perfusion.

Hemostemix (OTCQB: HMTXF) announced a non‑brokered private placement of up to $700,000 with a lead order of $330,000 on October 7, 2025. Units priced at $0.11 include one common share and one warrant exercisable at $0.15 for two years from closing.

Warrants include an accelerator: if the 10‑day weighted average closing price exceeds $0.185 after four months, expiry can be accelerated to 30 days after notice. A company director is participating, triggering related‑party disclosures; the company is relying on MI 61‑101 exemptions for valuation and minority approval. Proceeds are allocated to general working capital, including marketing and sales of VesCell™.

Hemostemix (OTCQB: HMTXF) has filed FDA Pre-IND Application 1517 for a basket protocol Phase I clinical trial of its lead therapy ACP-01 (VesCell™). The trial aims to evaluate safety, feasibility, and early efficacy of ACP-01 across multiple conditions including vascular dementia, peripheral arterial disease, angina, cardiomyopathy, and congestive heart failure.

The company plans to integrate real-world evidence from Florida, where ACP-01 is legally available under SB 1768, to support IND advancement and expedited regulatory designations. Hemostemix has completed 498 safe treatments to date and has 11 peer-reviewed publications demonstrating safety and efficacy.